Minimal residual disease combined with radiological tumor volume as a tool for identification of resected NSCLC patients at high risk of recurrence
Introduction Circulating tumor DNA (ctDNA) is a valuable tool for assessing minimal residual disease (MRD) and predicting recurrence in resected non-small cell lung cancer (NSCLC) patients. Combining ctDNA-detection with radiological tumor volume may improve risk stratification. Methods Patients with stage I-III resect...